This coin has everything going for it (From Crypto 101 Media)

Defense technology has been one of the market's most volatile and arguably talked-about themes in 2026, apart from artificial intelligence, of course. But the gains across the sector have been far from evenly distributed.

AeroVironment (NASDAQ: AVAV) is proof of that. While many of its peers have climbed, AVAV has fallen nearly 40% from where it began the year, leaving the drone and loitering-munitions maker as one of the sector's clear laggards. That is precisely what makes this week's news worth a closer look. The company just landed a landmark contract that could reframe the investment case, and it arrives with the stock trading near its 52-week low.

A Landmark Directed-Energy Award

On Sept. 2, AeroVironment announced the U.S. Army had awarded it a $464.8 million contract for its Enduring-High Energy Laser (E-HEL) program. Under the agreement, the company will produce dozens of its LOCUST X3 laser weapon systems over the next several years to defend against the small, low-flying drones that have reshaped the modern battlefield, a category the Pentagon labels Group 1 through 3.

What makes this more than just another defense contract is its historic nature. The award represents the first-ever production contract for directed energy systems in United States history, marking the moment laser weapons officially graduated from prototype to full-scale production. The LOCUST X3 is a 30-kilowatt, platform-agnostic system designed to integrate with vehicles such as the Army's Joint Light Tactical Vehicle and builds on years of successful field testing. For AVAV, it is validation that its bet on directed energy is beginning to pay off in a serious way.

What the Company Does

For those less familiar with the name, AeroVironment is a defense technology company best known as a pioneer in Unmanned Aerial Systems (UAS) and loitering munitions. Its Switchblade drones have become a staple of modern warfare, and the company has steadily expanded into counter-drone technology, an area of surging demand as militaries worldwide scramble to defend against cheap, proliferating aerial threats. The LOCUST award slots directly into that growing counter-UAS portfolio, adding a high-value production program to a business already anchored by a backlog of roughly $1.2 billion.

Fundamentals and Valuation

The fundamental picture is more mixed than the contract headline suggests, and investors should, as always, weigh both sides. AVAV generates annual revenue of nearly $2 billion, and analysts project earnings growth of close to 30% in the year ahead. But the company is currently unprofitable on a trailing basis, having posted a net loss of roughly $265 million over the past 12 months, which is why the stock trades at a forward multiple in the mid-40s rather than trailing earnings, which are negative. That forward valuation demands that the anticipated growth actually materializes, and leaves little to no room for disappointment.

The balance sheet offers some reassurance, with a low debt-to-equity ratio of 0.17 and a current ratio slightly above 4, indicating no immediate short-term solvency issues and leaving some room to fund its expansion. Production for the new contract will be supported by a $30 million investment in its Albuquerque, New Mexico, facility, announced earlier this year, a sign that management anticipated this ramp.

Institutional and Analyst Sentiment

Despite the beaten-down share price, the professional community remains overwhelmingly bullish. The stock carries a Moderate Buy consensus rating from the 24 analysts covering it, and the average price target of $266.68 implies a striking 81% upside from current levels.

Despite its clear year-to-date (YTD) lagging performance, institutions appear to view it as a clear mispricing and long-term opportunity. Over the prior 12 months, institutions have purchased $3.85 billion of AVAV stock, versus just $1.14 billion in sales, resulting in an impressive net inflow and current institutional ownership of slightly more than 86%.

Catalyst Meets Caution

AVAV has begun the month with a complex yet intriguing overall setup: a beaten-down defense innovator that just secured a historic, first-of-its-kind production contract, with analysts pointing to substantial upside. And another major catalyst is just around the corner; the company is set to announce its Q1 2027 earnings on Sept. 9 after the market closes.

The central question the LOCUST award raises is whether directed energy can become a meaningful new growth pillar for the company, and this contract is the strongest evidence yet that it can. The risks are just as real, though, from the trailing losses to the margin pressures to a share price that has spent the year falling. The LOCUST award does not erase a difficult year, but it does give investors a concrete reason to take a fresh look at a name the market had largely written off.

Read this article online ›